Nanopharmacia Group: HEALTH INNOVATION FOR LATIN AMERICA
The World Health Organization projects that the number of new cases of diabetes and cancer in Latin America could increase by more than 70% in the next decade. Preventing and combatting these diseases requires innovation and investment. The Mexican company Nanopharmacia Group offers both.
The company is rising to the challenges of health care in Mexico and Latin America. It is the only private company in Latin America in the business of developing new therapeutic products using nanotechnology to treat diabetes and cancer.
“Diabetes is a metabolic disease that has increased dramatically in Mexico in the last 10 years, and cancer is a complex disease closely linked to multiple factors including metabolic and infectious,” says Horacio Astudillo de la Vega, Nanopharmacia lead scientist, founder and partner.
Nanopharmacia Group integrates Nanopharmacia Diagnostica, a leader in precision cancer medicine in Mexico; Nanoclinic, a clinical laboratory diagnostic firm; Healthcare Business and Computer Technologies, which offers novel supplement combinations and medical device technologies; and DNI Genetics & Nutrition, developer of genetic metabolism diagnostics and personalized nutritional treatments. Each company is already active commercially with products and services, using 100% Mexicanowned scientific developments.
Nanopharmacia Group has evaluated more than 40,000 cases in the last eight years and serves patients with chronic degenerative diseases at both public and private institutions. Its private Nanopharmacia Foundation was established to further provide research and support for disease prevention and cures.
Improving Lives With Detection and Advanced Treatments
“In Mexico, a national program for timely detection has not been established,” says Astudillo de la Vega. “Diabetes treatment and detection strategies have not had a favorable impact on disease control in our country. In Latin America, the situation is no less serious, as in Mexico, the high cost of medical and pharmaceutical interventions is not accessible to the entire population.” By offering advanced early-detection and diagnostic tools, Nanopharmacia hopes to improve lives.
As it continues to innovate, the company is looking to expand the market for its supplement products. Some of these formulations, improved with the use of nanotechnology, have been proven beneficial for regulating the metabolic behavior of complex diseases such as diabetes and cancer. Some of Nanopharmacia’s supplement formulations have been granted patents in the United States, the EU and in more than 40 countries including China, India and Russia. Many more are in the pipeline.
Nanopharmacia’s product DIAKRONE developed by Nanopharmacia has demonstrated benefits for patients with diabetes and diabetic complications. DIAKRONE was approved by Mexico’s health and drug regulatory agency COFEPRIS to start the first study with diabetic patients, a step toward the product’s approval.
“The global market for advanced molecular diagnosis and supplements is one of the fastest growing in the world,” says Astudillo de la Vega. “It is estimated that it will reach more than $16 billion by 2025, especially for products that offer combinations with improved efficacy based on the use of nanotechnology as we are doing now. This segment of development in pharmaceutical and scientific innovation is undoubtedly the one with the greatest acceleration in investment for new businesses.”